公开(公告)号：US11684640B2

公开(公告)日：2023-06-27

申请号：US16472778

申请日：2017-12-22

申请人： INSTITUT GUSTAVE ROUSSY ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE-INSERM ,  UNIVERSITE PARIS-SACLAY ,  Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE)

发明人： Laurence Zitvogel ,  Bertrand Routy ,  Emmanuelle Le Chatelier

IPC分类号： A61K35/744 ,  A61K39/395 ,  C12Q1/6886 ,  C12Q1/689 ,  A61K39/00

CPC分类号： A61K35/744 ,  A61K39/39558 ,  C12Q1/689 ,  C12Q1/6886 ,  A61K2039/55594 ,  A61K2039/585 ,  C12Q2600/106 ,  C12Q2600/118

摘要： The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.